Fluzoparib plus apatinib for advanced ovarian cancer after chemotherapy
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage III or IV ovarian cancer (high-grade serous or endometrioid) that was diagnosed for the first time and was treated with chemotherapy that included carboplatin and paclitaxel (and possibly bevacizumab).
- You cannot have previously taken a PARP inhibitor (like olaparib) as maintenance therapy.
- You must be in generally good physical health (able to do light activity) and have good organ function.
- You must be able to swallow tablets and not have active bleeding or serious infections.
- Your cancer must not have spread to the brain, and any fluid in the belly or chest should be controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications (fluzoparib and apatinib) taken daily as maintenance therapy after your ovarian cancer has responded to chemotherapy. The goal is to keep the cancer from returning for as long as possible.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
This trial tests a combination of two oral medications (fluzopril and apatinib) as maintenance therapy after chemotherapy, for patients with platinum-resistant ovarian cancer. The goal is to see if this combo helps keep the cancer from growing longer than usual.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.